Stoke Therapeutics is a biotechnology company that is focused on developing treatments for severe genetic diseases. The company's approach is to use antisense oligonucleotides to increase gene expression levels in order to treat the underlying genetic cause of the disease. Stoke's lead program is focused on Dravet syndrome, a severe form of epilepsy that is caused by mutations in the SCN1A gene. The company is also developing programs for other genetic diseases, including genetic forms of ALS and Huntington's disease.